IDH1 and glioblastoma: Targeting IDH1 (isocitrate dehydrogenase 1) that is overexpressed in aggressive TETs (Table 3 and Table S6) using IDH1 Inhibitors such as GSK864 as reported in preclinical tests in glioblastomas could be a new therapeutic option, especially when used in combination with inhibitors of RTK-PI3K signaling [82].